Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17183061rdf:typepubmed:Citationlld:pubmed
pubmed-article:17183061lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0105770lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0664336lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C1565860lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C1705323lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0013081lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17183061lifeskim:mentionsumls-concept:C0556150lld:lifeskim
pubmed-article:17183061pubmed:issue6lld:pubmed
pubmed-article:17183061pubmed:dateCreated2007-6-4lld:pubmed
pubmed-article:17183061pubmed:abstractTextn-3 Polyunsaturated fatty acids have been shown to powerfully inhibit the growth of colon cancer cells, mainly acting as pro-apoptotic agents through inhibition of cycloxygenase-2 (COX-2) expression. Since dysregulation of beta-catenin expression is frequently found at early stage of colorectal carcinogenesis, we analyzed whether docosahexaenoic acid (DHA) may modify the expression of beta-catenin in colon cancer cells (SW480 and HCT116) over-expressing this protein, but lacking COX-2. Futhermore, we investigated if alterations in beta-catenin expression may be associated with apoptosis induction. Treatment of cells with increasing concentrations of DHA induced a dose- and time-dependent inhibition of beta-catenin protein expression which, however, was not accompanied by modifications in beta-catenin transcription. Conversely, the proteasomal inhibitors MG132 and lactacystin prevented DHA-induced beta-catenin decrease, suggesting that DHA may regulate the proteasomal degradation of beta-catenin. The reduced levels of beta-catenin were accompanied by decreased translocation of beta-catenin into the nucleus, where it acts as a transcription factor in concert with T-Cell Factor (TCF). DHA, at the same range of concentrations, was also able to induce apoptosis by a caspase-3-dependent mechanism and to cause a dose- and time-dependent decrease of survivin, an apoptosis inhibitor undetectable in normal tissues and expressed in colorectal cancer through TCF-beta-catenin stimulation. Several other proteins regulated by the TCF-beta-catenin pathway and involved in regulation of tumor growth were down-regulated by DHA, including peroxisome proliferator-activated receptor-delta, membrane type 1 (MT1)-matrix metalloproteinase (MMP), MMP-7 and vascular endothelial growth factor. The present study, thus, raises the possibility that DHA may exert pro-apoptotic and antitumoral effects through proteasomal regulation of beta-catenin levels and alterations in the expression of TCF-beta-catenin target genes.lld:pubmed
pubmed-article:17183061pubmed:languageenglld:pubmed
pubmed-article:17183061pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:citationSubsetIMlld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17183061pubmed:statusMEDLINElld:pubmed
pubmed-article:17183061pubmed:monthJunlld:pubmed
pubmed-article:17183061pubmed:issn0143-3334lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:PalozzaPaolaPlld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:SeriniSimonaSlld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:BoninsegnaAlm...lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:RanellettiFra...lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:CalvielloGabr...lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:ToescaAmeliaAlld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:PiccioniElisa...lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:MonegoGiovann...lld:pubmed
pubmed-article:17183061pubmed:authorpubmed-author:ResciFederica...lld:pubmed
pubmed-article:17183061pubmed:issnTypePrintlld:pubmed
pubmed-article:17183061pubmed:volume28lld:pubmed
pubmed-article:17183061pubmed:ownerNLMlld:pubmed
pubmed-article:17183061pubmed:authorsCompleteYlld:pubmed
pubmed-article:17183061pubmed:pagination1202-9lld:pubmed
pubmed-article:17183061pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:meshHeadingpubmed-meshheading:17183061...lld:pubmed
pubmed-article:17183061pubmed:year2007lld:pubmed
pubmed-article:17183061pubmed:articleTitleDocosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.lld:pubmed
pubmed-article:17183061pubmed:affiliationInstitute of General Pathology, Institute of Human Anatomy, Catholic University, Rome, Italy. g.calviello@rm.unicatt.itlld:pubmed
pubmed-article:17183061pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17183061pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17183061lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17183061lld:pubmed